Prakt. lékáren. 2021; 17(1): e14-e21 [Onkologie. 2020:14(6):263-267]

The sequence of antiVEGF(R) preparations in the treatment of metastatic colorectal carcinoma in 2020

Ivana Kosíková
Interní hematologická a onkologická klinika, FN Brno

Pathological angiogenesis plays a significant role in tumor growth and metastasis in colorectal carcinoma. Antiangiogenic therapy in combination with chemotherapy currently plays an irreplaceable role in the treatment of mCRC. The sequence of use of individual antiVEGF(R) preparations is based on the results of clinical trials. Currently, no biomarkers have been validated to determine which patients with mCRC would benefit the most from anti-VEGF therapies.

Keywords: metastatic colorectal carcinoma, antiangiogenic therapy, VEGF.

Published: April 15, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kosíková I. The sequence of antiVEGF(R) preparations in the treatment of metastatic colorectal carcinoma in 2020. Praktické lékárenství. 2021;17(1):e14-21.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ústav zdravotnických informací a statistiky ČR. Národní onkologický registr (NOR) online. Dostupné z: http://www.uzis.cz/registry-nzis.
    2. Weinberg BA, Hartley ML, Salem ME. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 2: Approaches Beyond First-Line Therapy, and Novel Biologic Agents Under Investigation. Oncology (Williston Park). 2017; 31(7): 573-580. Go to PubMed...
    3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23): 2335-2342. Go to original source... Go to PubMed...
    4. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007; 25(30): 4779-4786. Go to original source... Go to PubMed...
    5. Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007; 12(1): 38-50. Go to original source... Go to PubMed...
    6. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study [published correction appears in J Clin Oncol. 2008; 26(28): 4697]. J Clin Oncol. 2008; 26(21): 3523-3529. Go to original source... Go to PubMed...
    7. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22(2): 229-237. doi:10.1200/JCO.2004.05.113. Go to original source... Go to PubMed...
    8. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015; 16(13): 1306-1315. Go to original source... Go to PubMed...
    9. Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials [published correction appears in JAMA Oncol. 2017 Dec 1; 3(12): 1742]. JAMA Oncol. 2017; 3(2): 194-201. Go to original source... Go to PubMed...
    10. Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017; 28(8): 1713-1729. Go to original source... Go to PubMed...
    11. Strickler JH, Hurwitz Hl. Maintenence therapy for first-line metastatic colorectal cancer cancer: activity and sustainability. Oncologist 2012; 17: 9-10. Go to original source... Go to PubMed...
    12. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006; 24(3): 394-400. Go to original source... Go to PubMed...
    13. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009; 27(34): 5727-5733. doi:10.1200/JCO.2009.23.4344. Go to original source... Go to PubMed...
    14. Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385(9980): 1843-1852. Go to original source... Go to PubMed...
    15. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013; 14(1): 29-37. Go to original source... Go to PubMed...
    16. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28): 3499-3506. Go to original source... Go to PubMed...
    17. Tabernero J, Yoshino T, Cohn AL, et al. RAISE Study Investigators. Ramucirumab versus placebo in combination with second - line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during o rafter first-line therapy with bevacizumab, oxaliplatin, and fluoropyrimidine (RAISE): a randomised, double blind, multicentre, phase 3 study. Lancet Oncol 2015; 16: 499-508. Go to original source... Go to PubMed...
    18. Hecht JR, Cohn A, Dakhil S, et al. SPIRITT: A randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer 2015; 14: 72-80. Go to original source... Go to PubMed...
    19. Bennouna J, Hiret S, Borg C, et al. Bevacizumab or cetuximab plus chemoterapy after progression with bevacizumab plus chemoterapy in patients with wild-type KRAS metastatic colorectal cancer.: Final anylsis of a French randomized, multicenter, phase II study (PRODIGE 18). Ann Oncol 2017; 28(suppl_5) Go to original source...
    20. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863): 303-312. Go to original source... Go to PubMed...
    21. Bekaii-Saab TS, Ou FS, Ahn DH, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019; 20(8): 1070-1082. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.